Avalo Therapeutics, Inc. (AVTX)
13.65
+0.22
(+1.64%)
USD |
NASDAQ |
Oct 09, 16:00
13.65
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics EPS Diluted (Quarterly) : -0.8339 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.8339 |
| March 31, 2026 | -0.9763 |
| December 31, 2025 | -0.7411 |
| September 30, 2025 | -2.187 |
| June 30, 2025 | -1.917 |
| March 31, 2025 | -1.250 |
| December 31, 2024 | -3.375 |
| September 30, 2024 | -2.834 |
| June 30, 2024 | -14.07 |
| March 31, 2024 | -141.14 |
| December 31, 2023 | -10.19 |
| September 30, 2023 | -26.83 |
| June 30, 2023 | -140.73 |
| March 31, 2023 | -203.81 |
| December 31, 2022 | -249.96 |
| September 30, 2022 | 81.38 |
| June 30, 2022 | -331.55 |
| March 31, 2022 | -563.04 |
| December 31, 2021 | -492.42 |
| September 30, 2021 | -498.53 |
| June 30, 2021 | -506.71 |
| March 31, 2021 | -931.65 |
| December 31, 2020 | -554.05 |
| September 30, 2020 | -478.02 |
| Date | Value |
|---|---|
| June 30, 2020 | -555.49 |
| March 31, 2020 | -970.07 |
| September 30, 2019 | -219.02 |
| June 30, 2019 | -375.90 |
| March 31, 2019 | -427.42 |
| December 31, 2018 | -509.67 |
| September 30, 2018 | -2045.06 |
| June 30, 2018 | -536.57 |
| March 31, 2018 | -357.09 |
| December 31, 2017 | -725.39 |
| September 30, 2017 | 1497.60 |
| June 30, 2017 | -403.20 |
| March 31, 2017 | -547.20 |
| December 31, 2016 | -518.40 |
| September 30, 2016 | -2016.00 |
| June 30, 2016 | -1180.80 |
| March 31, 2016 | -1699.20 |
| December 31, 2015 | -1526.40 |
| September 30, 2015 | -230.63 |
| June 30, 2015 | -972.03 |
| March 31, 2015 | -1080.46 |
| June 30, 2014 | -1356.28 |
| March 31, 2014 | -1210.78 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.033 |
| Rezolute, Inc. | -0.1961 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -36.36M |
| Total Expenses (Quarterly) | 36.36M |
| Enterprise Value | 324.01M |
| Earnings Yield | -34.72% |
| Normalized Earnings Yield | -30.79 |